Drug Profile
Triabin
Latest Information Update: 27 Jul 2005
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer PAION
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 27 Jul 2005 No development reported - Preclinical for Thrombosis in Germany (unspecified route)
- 30 Jan 2003 Preclinical trials in Thrombosis in Germany (unspecified route)
- 29 Jan 2003 Triabin has been licensed to PAION